Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).

Mirza KA, Wyke SM, Tisdale MJ.

Br J Cancer. 2011 Jun 28;105(1):83-8. doi: 10.1038/bjc.2011.216. Epub 2011 Jun 14.

2.
3.

Mechanism of muscle protein degradation induced by a cancer cachectic factor.

Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ.

Br J Cancer. 1998 Oct;78(7):850-6.

4.

Catabolic mediators of cancer cachexia.

Tisdale MJ.

Curr Opin Support Palliat Care. 2008 Dec;2(4):256-61. Review.

PMID:
19069310
5.

Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II.

Russell ST, Eley H, Tisdale MJ.

Cell Signal. 2007 Aug;19(8):1797-806. Epub 2007 Apr 19.

PMID:
17532611
6.

Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation.

Eley HL, Tisdale MJ.

J Biol Chem. 2007 Mar 9;282(10):7087-97. Epub 2007 Jan 9.

7.

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.

Mirza KA, Tisdale MJ.

Br J Cancer. 2014 Aug 26;111(5):903-8. doi: 10.1038/bjc.2014.379. Epub 2014 Aug 7.

9.

Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF).

Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ.

Br J Cancer. 2001 Jul 20;85(2):297-302.

10.

Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice.

Siddiqui RA, Hassan S, Harvey KA, Rasool T, Das T, Mukerji P, DeMichele S.

Br J Nutr. 2009 Oct;102(7):967-75. doi: 10.1017/S0007114509345250. Epub 2009 Apr 27.

PMID:
19393114
11.
12.

Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate.

Russell ST, Siren PM, Siren MJ, Tisdale MJ.

Cancer Chemother Pharmacol. 2009 Aug;64(3):517-27. doi: 10.1007/s00280-008-0899-z. Epub 2008 Dec 27.

PMID:
19112551
13.

Changes in nucleic acid and protein levels in atrophying skeletal muscle in cancer cachexia.

Bhogal AS, Lorite ML, Tisdale MJ.

Anticancer Res. 2006 Nov-Dec;26(6B):4149-54.

14.

Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.

Hussey HJ, Todorov PT, Field WN, Inagaki N, Tanaka Y, Ishitsuka H, Tisdale MJ.

Br J Cancer. 2000 Jul;83(1):56-62.

15.

Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361).

Todorov PT, Field WN, Tisdale MJ.

Br J Cancer. 1999 Aug;80(11):1734-7.

16.

The 'cancer cachectic factor'.

Tisdale MJ.

Support Care Cancer. 2003 Feb;11(2):73-8. Epub 2002 Nov 5.

PMID:
12560934
17.

Loss of skeletal muscle in cancer: biochemical mechanisms.

Tisdale MJ.

Front Biosci. 2001 Feb 1;6:D164-74. Review.

PMID:
11171557
18.

Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes.

Yano CL, Ventrucci G, Field WN, Tisdale MJ, Gomes-Marcondes MC.

BMC Cancer. 2008 Jan 28;8:24. doi: 10.1186/1471-2407-8-24.

19.
20.

Supplemental Content

Support Center